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Abstract
Viral vectored vaccines have been shown to induce both T cell and antibody responses in animals and humans. However,
the induction of even higher level T cell responses may be crucial in achieving vaccine efficacy against difficult disease
targets, especially in humans. Here we investigate the oligomerization domain of the a-chain of C4b-binding protein (C4 bp)
as a candidate T cell ‘‘molecular adjuvant’’ when fused to malaria antigens expressed by human adenovirus serotype 5
(AdHu5) vectored vaccines in BALB/c mice. We demonstrate that i) C-terminal fusion of an oligomerization domain can
enhance the quantity of antigen-specific CD4+ and CD8+ T cell responses induced in mice after only a single immunization
of recombinant AdHu5, and that the T cells maintain similar functional cytokine profiles; ii) an adjuvant effect is observed for
AdHu5 vectors expressing either the 42 kDa C-terminal domain of Plasmodium yoelii merozoite surface protein 1 (PyMSP142)
or the 83 kDa ectodomain of P. falciparum strain 3D7 apical membrane antigen 1 (PfAMA1), but not a candidate 128kDa P.
falciparum MSP1 biallelic fusion antigen; iii) following two homologous immunizations of AdHu5 vaccines, antigen-specific T
cell responses are further enhanced, however, in both BALB/c mice and New Zealand White rabbits no enhancement of
functional antibody responses is observed; and iv) that the T cell adjuvant activity of C4 bp is not dependent on a functional
Fc-receptor c-chain in the host, but is associated with the oligomerization of small (,80 kDa) antigens expressed by
recombinant AdHu5. The oligomerization domain of C4 bp can thus adjuvant T cell responses induced by AdHu5 vectors
against selected antigens and its clinical utility as well as mechanism of action warrant further investigation.
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Introduction
The development of highly efficacious vaccines against difficult
disease targets such as malaria, tuberculosis (TB), HIV-1 and
pandemic influenza, will likely require the induction of strong
cellular immunity as well as antibody responses. Whilst classical
protein-in-adjuvant vaccines primarily induce antibodies, viral
vectored vaccines are being developed as a means of inducing both
T cell and antibody responses [1]. Encouragingly, new generation
vaccine delivery platforms, primarily based on recombinant
adenovirus and poxvirus prime-boost immunization regimes, are
capable of inducing T cell responses in non-human primates [2–5]
and humans [6–9] of a higher magnitude than ever reported
before. However, the development of adjuvants to enhance the T
cell responses induced by viral vectored vaccines may be crucial to
the ultimate development of highly effective vaccines against such
difficult infectious diseases and cancers.
The oligomerization domain of complement C4b-binding
protein (C4 bp) a-chain has been identified as an adjuvant of
antibody responses in both protein and viral vectored vaccination
regimes [10,11]. Full-length native C4 bp is an inhibitor of the
classical and lectin pathways of complement activation. It consists
of seven a-chains, one of which may be replaced by a b-chain in
humans, linked together by a heptamerization domain at the C-
terminus of the a-chains [12]. This oligomerization domain is 57
amino acid residues in humans and 54 amino acid residues in
mice. It contains an amphipathic a-helix region, which is
necessary and sufficient for heptamerization, as well as two
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cysteine residues which stabilize the structure [13]. Previous
studies have shown that fusion of this domain to other proteins
causes them to oligomerize [10,14–16]. When the murine C4 bp
oligomerization domain (henceforth known as IMX108 [10]) was
fused to the 19 kDa C-terminal domain of Plasmodium yoelii
merozoite surface protein 1 (PyMSP119) recombinant protein it
increased antigen-specific antibody responses following vaccina-
tion and enhanced protection against challenge with red blood
cells infected with P. yoelii (pRBC) in mice [10]. Furthermore,
when this domain is fused to PyMSP142 in human adenovirus
serotype 5 (AdHu5) and modified vaccinia virus Ankara (MVA)
viral vectored vaccines and given in a prime-boost regime eight
weeks apart (Ad-M42), then enhanced antibody responses are
induced [11]. Although T cell responses were also apparently
increased in that study, this finding appeared less consistent so
here we have investigated T cell immunogenicity in detail using
each vector alone with multiple blood-stage malaria antigens each
fused to the oligomerization domain of C4 bp.
In a previously reported study, immunization of mice with
murine C4 bp (PyMSP119+IMX108 fusion protein) led to the
induction of auto-antibodies against murine C4 bp [10]. This led
the authors to test the C4 bp a-chain oligomerization domains
from a variety of other mammalian and avian species for adjuvant
activity in mice without induction of auto-antibodies [10]. All the
C4 bp oligomerization domains tested formed soluble heptameric
proteins, and induced higher antigen-specific antibody titers in
mice than PyMSP119 protein alone or in Freund’s adjuvant. The
most immunogenic form, termed IMX313, is a hybrid derived
from the oligomerization domains of the two chicken orthologues
of C4 bp a-chain. It was designed to minimize similarity to
mammalian C4 bp a-chain domains and has less than 20% amino
acid identity to human C4 bp. The IMX313 sequence therefore
minimizes the potential for auto-antibody induction in humans,
and is a candidate ‘‘molecular adjuvant’’ for enhancement of
vaccine-induced immune responses in humans. This construct has
also recently been tested as a C-terminal fusion to the Mycobacterium
tuberculosis antigen 85A in the clinical vaccine candidate MVA85A
and significantly increased immune responses in both mice and
rhesus macaques [17].
Surprisingly, in the recombinant protein vaccine study by Ogun
et al., the antibody titers induced against PyMSP119 (when fused to
different C4 bp a-chain oligomerization domain homologues)
varied significantly, and the majority led to significantly higher
antibody titers than a non-related heptameric oligomerization
domain from P. abyssi [10]. It was therefore hypothesized that
antigen oligomerization is not the sole mechanism explaining the
adjuvant activity of this structural motif. The central core domain
of C4 bp has been reported to contribute to binding CD40 on B
cells [18], as well as to the pentraxins, serum amyloid P
component (SAP) [19,20] and C-reactive protein (CRP) [21].
We therefore hypothesized that adjuvant activity may occur due to
binding of the oligomerization domain of C4 bp to these acute-
phase proteins. These proteins can function by binding Fcc
receptors (FccR) on leukoctyes, resulting in enhanced FccR-
mediated phagocytosis and cytokine secretion [22], which may
consequently lead to an enhanced adaptive immune response. An
alternative hypothesis is that oligomerization of the vaccine
antigen may lead to formation of immune complexes following
antibody induction, therefore enhancing activation via FccR.
The studies presented here represent an iterative process of
vaccine development. Initial studies show that C-terminal fusion of
the murine oligomerization domain IMX108 to P. yoelii MSP142
can increase the magnitude of the T cell response induced by
adenoviral vectored vaccines in mice. Given these promising
results, as well as our previously published results [11], we then
tested the IMX313 variant, which is suitable for use in humans,
fused to P. falciparum blood-stage antigen clinical constructs
[6,7,23,24]. Here we demonstrate that IMX313 can similarly
increase the magnitude of T cell responses induced by adenoviral
vectors in mice. We find that the observed adjuvant activity is
associated with oligomerization of small (,80 kDa) antigens and is
not dependent on a functional Fc-receptor c-chain in the host.
Results
IMX108 Enhances T Cell, but not Antibody Responses,
Following a Single Immunization with AdHu5-PyMSP142
We have previously demonstrated that following priming with
AdHu5 and boosting eight weeks later with MVA, both expressing
PyMSP142 fused to IMX108, antigen-specific IgG and CD4
+IFN-
c+ responses are significantly increased compared to the same
immunization regime with vectors expressing PyMSP142 without
an IMX108 fusion. CD8+IFN-c+ responses also trended towards
being higher, but were not significant, and enhanced protection
against blood-stage P. yoelii challenge was observed [11]. In these
experiments immunogenicity after a single vaccination was not
assessed. A previous study adjuvanting an AdHu35 vector with
aluminium phosphate (AdjuPhos) showed a clear dose sparing
effect of the adjuvant [25], and thus in order to test whether
IMX108 could enhance immunogenicity after a single immuni-
zation, we immunized BALB/c mice with two different doses of
AdHu5-PyMSP142 with or without IMX108 (hereafter known as
Ad42-IMX108 or Ad42-Nil). Vaccines were given by the
intramuscular route (i.m.) as this is the route used for clinical
administration in our recent vaccine trials [6,7]. Following a single
immunization, the frequency of antigen-specific CD8+ T cell
responses at the higher dose was significantly increased in terms of
cells positive for IFN-c, TNFa and IL-2 if the vaccine included
IMX108 (Figure 1A). At the lower dose, only IL-2 was significantly
increased if the vaccine included IMX108. IFN-c and TNFa
responses trended towards being higher with IMX108, but did not
reach statistical significance (P = 0.0556 for both cytokines)
(Figure 1A). This is consistent with the dose sparing effect
observed by Ophorst et al. [25]. It has been suggested that the
multi-functional ‘‘quality’’ of T cells in terms of the number of
cytokines produced may be important for protection against
Leishmania major [26] and liver-stage P. berghei malaria in mice [27].
Given an adjuvant may potentially change the functionality or
phenotype of the T cells induced, we also analyzed cells for their
ability to co-produce the three cytokines tested using intracellular
cytokine staining (ICS) and flow cytometry. This revealed that the
‘‘quality’’ of the CD8+ T cell response in terms of the proportion of
cells producing all three cytokines (3+, IFN-c+TNFa+IL-2+), two
cytokines (2+, predominantly IFN-c+TNFa+IL-22) or a single
cytokine (1+, predominantly IFN-c+TNFa-IL-22) was unaffected
by addition of IMX108 to the PyMSP142 antigen (Figure 1A). A
trend towards increased CD4+ responses was observed with
IMX108 at both doses, with significantly greater production of
IFN-c at the high dose, and greater production of TNFa at the
lower dose (Figure 1B). However, these CD4+ responses were too
low for accurate multi-functional analysis (data not shown). Also,
in contrast to the responses observed following an Ad-MVA
prime-boost immunization regime [11], or a PyMSP119 protein
immunization [10], following a single Ad42 vaccination total
PyMSP119-specific IgG was not enhanced by IMX108 (Figure 1C).
Adenoviral vectors may be titered by two different methods,
either by assessing infectious units (ifu) or by counting viral
particles (vp). The measure of infectious units includes only
C4 bp Can Adjuvant Adenoviral Vectored Vaccines
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antigen-producing viable virus, whilst vp also includes non-viably
packaged DNA. We have found that ifu more accurately reflects
immunogenicity [28], although clinically adenoviral vaccines are
still administered based on dosing in vp [29]. We therefore also
assessed whether the adjuvant effect was observed when mice were
immunized based on vp. BALB/c mice were immunized i.m. with
1010 vp or 108 vp, or with 108 vp i.d. AdHu5-PyM-
SP1426IMX108 and a similar adjuvant effect for CD8
+ T cell
responses was observed (Figure S1). Furthermore, as expected the
comparable responses were observed whether the vaccine was
given by the i.m. or i.d. route (responses were not significantly
different by two-way ANOVA for any cytokine tested). This is in
agreement with previously published data in mice [30] and
humans [8].
Immunogenicity of AdHu5 Vaccines Expressing PfAMA1
and PfM128 with IMX313
A number of viral vectored vaccines encoding P. falciparum
antigens are currently being tested in Phase I/IIa clinical trials in
Oxford, UK [6–8] These include both adenoviral and MVA
vectors expressing the P. falciparum antigens apical membrane
antigen 1 (PfAMA1) [3,24] and an optimized composite version of
MSP1 (PfMSP1), termed PfM128 [23,30]. The latter comprises a
fusion of conserved blocks of PfMSP1 fused to both the Wellcome
and 3D7 alleles of PfMSP142 [23]. Given the enhanced T cell
immunogenicity observed with AdHu5 and MVA vectors
expressing the rodent malaria antigen PyMSP142 with the murine
form of the C4 bp oligomerization domain, IMX108, we
investigated whether immunogenicity of these candidate P.
falciparum antigens could be similarly enhanced. We generated
AdHu5 vectors expressing each of these antigens fused to the
hybrid chicken oligomerization domain, IMX313. This domain
has been optimized for minimal sequence homology with human
C4 bp a-chain oligomerization domain, is a candidate sequence
for clinical development and has potent adjuvant activity when
fused to PyMSP119 protein [10] and the TB antigen 85A
expressed by MVA [17]. When mice were immunized with
AdHu5-PfAMA1 with or without IMX313 (AdAMA1-IMX313
and AdAMA1-Nil respectively), the frequency of antigen-specific
IFN-c and TNFa expressing CD8+ and CD4+ T cells in the blood
of mice immunized with AdAMA1-IMX313 was significantly
increased (in comparison to AdAMA1-Nil), as measured by ICS
three weeks post-immunization (Figure 2A). Antigen-specific IL-2
positive CD4+ cells also showed a trend towards increased
frequency, although this did not reach statistical significance
(Figure 2A). In this experiment responses were measured in the
blood, rather than the spleen, so that mice could be kept alive for
further experiments. However, a similar result was observed when
AMA1-specific responses in the spleen were measured by IFN-c
ELISPOT in an independent experiment (Figure S3). Antibody
titers were also assayed by ELISA, and similar to the previous
experiments with Ad42-IMX108, total antigen-specific IgG was
not increased following immunization with a single dose of
AdAMA1-IMX313 as compared to AdAMA1-Nil (Figure 2B).
In contrast to the results with PfAMA1 and PyMSP142, after
mice were immunized with AdHu5-PfM128 with or without
IMX313 (AdPfM128-IMX313 or AdPfM128-Nil), MSP1-specific
IFN-c CD8+ T cell frequency in a spleen ELISPOT assay was not
enhanced by the presence of IMX313 (Figure 2C). Furthermore,
total PfMSP119-specific IgG was of significantly lower titer if the
vaccine contained IMX313 (P = 0.0032) (Figure 2D).
Oligomerization of the Antigen in vitro may be
Insufficient for in vivo Adjuvantation
Given that we observed a significant enhancement of T cell
responses following AdHu5 vaccination with PyMSP142 and
PfAMA1 if the constructs included the oligomerization domain,
Figure 1. Adjuvant activity of IMX108 following immunization
with AdHu5-PyMSP142. BALB/c mice were immunized i.m. with
1.56109 or 1.56107 ifu AdHu5-PyMSP1426IMX108 (Ad42-IMX108 or
Ad42-Nil). Fourteen days post immunization splenocytes were re-
stimulated with PyMSP133 peptides and assessed for frequency of IFN-c,
IL-2, and TNFa positive CD8+ (A) and CD4+ (B) T cells by ICS. Box and
whisker plots show median, IQR and range. The pie charts show the
functional composition of the response and represent the proportion of
PyMSP133
2specific CD8+ T cells positive for 1, 2 or all 3 cytokines
measured. Fourteen days post-immunization total PyMSP119-specific
IgG responses were measured by ELISA (C). Data points represent
individual mice and bars indicate median titer. n = 5 mice per group.
**P,0.01, *P,0.05 compared to AdHu5-PyMSP142+IMX108 at the same
dose by Mann Whitney test. Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0044943.g001
C4 bp Can Adjuvant Adenoviral Vectored Vaccines
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e44943
but failed to see enhanced responses with PfM128-IMX313, we
assessed whether PfAMA1 and PfM128 were indeed oligomerized
by addition of the C4 bp domain. Western blotting revealed the
presence of large molecular weight species, presumably heptamers,
with both antigens (Figure 3). For un-fused PfAMA1 under
reducing conditions monomers were observed. These were slightly
faster migrating than the expected size of 83 kDa for the full
ectodomain [31], and ran slower than the band observed with the
66 kDa PfAMA1 ectodomain recombinant protein, possibly
indicating post-translational modification. The PfAMA1-
IMX313 construct migrated slightly slower than PfAMA1 alone,
indicating a higher molecular weight due to the addition of the
IMX313 sequence. Under non-reducing conditions, larger bands
were observed for all PfAMA1 proteins tested, presumably due to
dimer formation. However, in the case of PfAMA1-IMX313, a
much larger species was observed at the very top of the molecular
weight range indicating that multimeric antigen was also present.
A PfAMA1-IMX313 heptamer has an expected molecular weight
of approximately 570 kDa. Although it is impossible to tell
whether this species was precisely heptameric, these multimers
were reduced upon addition of b-mercaptoethanol, in agreement
with the known intermolecular disulphide bonds in this region of
C4 bp [13]. These results are similar to those recently reported
which show that IMX313 fused to the M. tuberculosis antigen 85A
and delivered in an MVA vaccine induces enhanced T cell
responses following antigen multimerization [17]. Interestingly, for
the PfM128 antigen, a protein of the expected size (128 kDa) was
observed in both reducing and non-reducing conditions. However,
under non-reducing conditions this band was relatively weak and a
large amount of protein in excess of 230 kDa was observed, again
suggesting the presence of multimers. Under reducing conditions
this large protein was no longer observed, and both monomers and
Figure 2. Adjuvant activity of IMX313 following immunization with AdHu5-PfAMA1 or AdHu5-PfM128. BALB/c mice were immunized
i.m. with 16109 ifu AdHu5-PfAMA16IMX313 (AdAMA1-IMX313 and AdAMA1-Nil). Twenty-one days post-immunization frequency of IFN-c, TNFa and
IL-2 positive CD8+ and CD4+ T cells was assessed in the blood by ICS following stimulation with PfAMA1 peptides (A). Antigen-specific total IgG was
assessed by ELISA (B). Points represent individual mice and bars indicate median responses (n = 5–6 mice per group). **P,0.01, *P,0.05 compared to
AdAMA1-IMX313 by Mann Whitney test. Data show the results of a single experiment. A similar result was observed by spleen IFN-c ELISPOT (Figure
S3). In a separate experiment, mice were immunized i.m. with 16107 ifu AdHu5-PfM1286IMX313 (AdPfM128-IMX313 and AdPfM128-Nil). Fourteen
days later mice were culled and PfMSP133-specific IFN-c positive splenocytes were measured by ELISPOT (C). Data shown are spot forming units (SFU)
per 106 splenocytes. PfMSP119-specific total IgG was assessed by ELISA (D). Bars indicate median responses (n = 5 mice per group). Box and whisker
plots indicate median, IQR and range. The dashed line indicates the limit of detection. + P,0.05 compared to AdPfM128-IMX313 by Mann Whitney
test.
doi:10.1371/journal.pone.0044943.g002
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dimers were present in greater quantities. These data therefore
suggest that multimers are formed if the construct for both
AdHu5-PfAMA1 and AdHu5-PfM128 includes IMX313. How-
ever, given the differences in adjuvantation seen for these two
antigens, this property alone of the expressed antigen observed in
vitro does not necessarily predict the ability of the motif to lead to
enhanced T cell immunogenicity in vivo.
Adjuvant Activity of IMX108/IMX313 in Homologous
Prime-boost Regimes
Given the lack of adjuvant effect of IMX108 on IgG responses
after a single immunization with AdHu5-PyMSP142, but the
observed adjuvant effect on IgG previously reported after an Ad-
MVA prime-boost regime (Ad42-M42) [11], we investigated
whether a homologous adenovirus boost could enhance IgG.
Mice were immunized twice with AdHu5-PyMSP1426IMX108,
eight weeks apart (Ad42-Ad42). Fourteen days after the second
immunization mice were culled and T cell and antibody responses
assayed. Similar to a single immunization with Ad42 (Figure 1), or
Ad42-M42 vaccination [11], CD4+ and CD8+ T cell responses
trended towards increased frequency when IMX108 was fused to
the antigen, with numbers of IFN-c positive CD8+ and CD4+ T
cells being significantly higher (Figure 4A). However, unlike prime-
boost vaccination with Ad42-M42 [11], following Ad42-Ad42
immunization total PyMSP119-specific IgG was not affected by
addition of IMX108 (Figure 4D).
Similar experiments were carried out with AdHu5-PfAMA1.
Mice were immunized with 16109 ifu AdHu5-PfAMA16IMX313
i.m. twice (8 weeks apart) and T cell responses in the spleen were
assayed by ICS two weeks after the boost. Overall, T cell responses
were significantly higher than those observed following a single
immunization with AdHu5-PfAMA1 (Figure 2A). Frequency of
IFN-c or TNFa positive CD8+ T cells was significantly higher
when IMX313 was fused to PfAMA1, although IL-2 was almost
undetectable even in the IMX313 group (Figure 4C). Production
of all three cytokines from CD4+ T cells was significantly higher in
the presence of IMX313. Again, however, antigen-specific total
IgG was not enhanced by IMX313 (Figure 4E).
To investigate the role of MVA in enhanced antibody
responses, mice were immunized twice with MVA-PyM-
SP1426IMX108 eight weeks apart (M42-M42). Following the
Figure 3. Schematic representation of PfAMA1±IMX313 and PfM128±IMX313 and assessment of antigen oligomerization by
western blotting. Schematic representation of PfAMA16IMX313 (A) and PfM1286IMX313 (B) constructs are shown; human tissue plasminogen
activator signal peptide (tPA) (30 aa), PfAMA1 (521 aa), PfM128 (1111 aa) and IMX313 (55 aa). PfAMA1 3D7 protein was included as a positive control.
Western blots probed with mouse anti-PfAMA1 polyclonal antibody (C) and mouse anti-PfMSP119 polyclonal antibody (D) under both reducing and
non-reducing conditions. To the left of each column, * indicates presumed dimers and # indicates presumed multimers. Control AdHu5 infected
lysate without the antigen of interest was also included and no bands were observed (data not shown).
doi:10.1371/journal.pone.0044943.g003
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Figure 4. Adjuvant activity of IMX108/IMX313 in homologous prime-boost regimes. Frequency of antigen-specific IFN-c, TNFa and IL-2
positive CD4+ and CD8+ T cells in the spleen were measured by ICS fourteen days post-boost following two immunizations with 561010 vp AdHu5-
PyMSP1426IMX108 i.d. (Ad-Ad42+IMX108 and Ad-Ad42-Nil respectively) (A), 56107 pfu MVA-PyMSP1426IMX108 i.d. (M-M42+IMX108 and M-M42-Nil)
(B) or 16109 ifu AdHu5-PfAMA16IMX313 i.m. (Ad-AdAMA1+IMX313 and Ad-AdAMA1-Nil) (C). Immunizations were given eight weeks apart. Box and
whisker plots show median, IQR and range and pies show the proportion of cells positive for 1, 2 or all 3 cytokines. Antigen-specific total IgG
responses were also measured in the serum fourteen days after boost by ELISA (D-F). Points represent individual mice and bars indicate median titer.
The dashed line indicates the limit of detection. **P,0.01, *P,0.05 compared to the same vaccination regime with IMX108 or IMX313 by Mann
Whitney test. Data show the results of single experiments.
doi:10.1371/journal.pone.0044943.g004
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first immunization T cell and antibody responses were not
detectable (data not shown). These data are consistent with the
known poor suitability of MVA as a priming agent [1]. Following
two immunizations, weak CD8+IFN-c+ responses could be
detected by ICS and were significantly higher if the vaccine
included IMX108 (P = 0.029) (Figure 4B). Furthermore,
PyMSP119-specific IgG was detectable following vaccination with
MVA expressing PyMSP142 fused to IMX108, but not without
(Figure 4F).
Ad-AdAMA1-IMX313 does not Enhance Functional
Antigen-specific IgG in Rabbits
We also investigated whether IMX313 could enhance antibody
responses in rabbits. New Zealand white rabbits were vaccinated
i.m. with 16109 or 56107 ifu AdHu5-PfAMA16IMX313 and
boosted with the same vaccine 8 weeks later (Ad-AdAMA1-
IMX313 or Ad-AdAMA1-Nil). The vaccines induced PfAMA1-
specific IgG, but IMX313 did not significantly enhance antibody
responses at any time-point at either the high or the low dose
(Figure 5A), as was observed in mice. Purified IgG from sera taken
on day 84 post priming immunization was tested for growth
inhibitory activity (GIA) in vitro against P. falciparum. At the
standard concentration of IgG used in the assay (2.5 mg/mL), the
majority of rabbits showed moderate to high levels of GIA, with
the exception of one rabbit in each of the low dose groups, and one
rabbit that had the vaccine without IMX313 at the high dose
(Figure 5B). Similar to previous studies [32], the GIA showed a
sigmoidal relationship with ELISA titer of the purified IgG.
However, there was no significant difference in the GIA of sera
from rabbits that had been immunized with vaccines including
IMX313 and those which had not. These data indicate that
IMX313 altered neither the titer nor the functional activity of the
antibodies induced. Higher levels of GIA were observed when IgG
was used at 5 mg/mL in the assay, however, again no significant
differences between vaccines was observed (data not shown).
Adjuvant Activity of the C4 bp Oligomerization Domain is
not Dependent on the FcR Common c-chain
Given the hypothesis that CRP and SAP binding to the
oligomerization domain and then to FccR may be the mechanism
of IMX108/313 adjuvant activity, we investigated whether an
adjuvant effect could still be observed in mice that were deficient
in the FcR c-chain (FcRc2/2) which is common to the FccRI,
FccRIII, FccRIV and FceRI [33,34] in mice. FcRc2/2 mice were
immunized with AdHu5-PyMSP1426IMX108. Two weeks later
the mice were culled and PyMSP133-specific CD8
+ T cell
responses in the blood were assayed by ICS and anti PyMSP119-
specific IgG responses were measured by ELISA. This showed that
enhanced T cell responses due to IMX108 also occurred in the
FcR common c-chain knockout mice (Figure 6A), but antibody
responses, like in wild-type mice, remained comparable
(Figure 6B). These data indicate that FccR that utilize the
common c-chain do not play a role in the T cell adjuvant activity
of the C4 bp oligomerization domain. The knockout also did not
appear to affect overall immunogenicity of the vaccination
regimen, suggesting that the FcR c-chain is not involved in
priming immune responses induced by adenoviral vectored
vaccines.
Discussion
These data show that the C4 bp a-chain heptamerization
domain can effectively adjuvant antigen-specific T cell responses
to some, but not all, antigens when fused to their C-termini and
delivered by an adenoviral vectored vaccine. Fusion of the domain
led to enhanced production of antigen-specific IFN-c, TNFa and
IL-2 from both CD8+ and CD4+ cells following vaccination with
AdHu5 vectors expressing PyMSP142 or PfAMA1. The adjuvant
did not affect the multi-functional quality of the CD8+ T cells
induced in terms of the cytokines assessed by multi-parameter flow
cytometry, but rather increased the frequency of cells positive for
all three cytokines proportionately. These data are in contrast to
some classical adjuvants, which skew responses towards produc-
tion of Th1- or Th2-type cytokines [35].
This adjuvant activity is likely not solely dependent upon
oligomerization of the antigen as no in vivo adjuvant effect was
observed with the PfM128-IMX313 construct. However, this
possibility cannot be ruled out because the PfM128-IMX313
western blot did not clearly identify whether this construct induces
oligomers efficiently. One possible explanation of the failure of
IMX313 to adjuvant T cells against the PfM128 antigen, may be
that adjuvanticity requires not only oligomerization of the antigen,
but also efficient extracellular secretion of such oligomeric
complexes. Western blots were carried out using cell lysate and
did not assess whether the antigens were secreted. PfM128-
IMX313 is 1165 amino acids (aa) in length, whilst PyM-
SP142
_IMX108 is only 447 aa and PfAMA1-IMX313 is 624 aa.
The large size of this protein in multimeric form may prevent it
being efficiently secreted. Furthermore the antigen comprises a
non-physiological fusion of blocks 1, 3, 5, 12, 16 and 17 of
PfMSP1, which may impair secretion. Biswas et al. have shown
that biallelic AMA1 expressed by adenoviral vectors is secreted
[24]. Given that both cellular and humoral immune responses to
this construct were lower than those observed with PfM128-Nil, it
is possible that increasing the size of this large antigen even further
was more detrimental, than beneficial, to efficient transgene
expression. However, the finding that adjuvant activity did not
occur for PfM128-IMX313, despite intracellular oligomerization
of the antigen, does not exclude the possibility that oligomerization
is a key factor in the adjuvanticity of this structural motif, provided
that the protein is sufficiently secreted.
Due to the iterative nature of this study, in which the murine
variant, IMX108, was tested with a P. yoelii antigen and then the
variant suitable for use in humans, IMX313, was tested with
P. falciparum antigens, a direct comparison between the adjuvant
activity of IMX108 and IMX313 for a single antigen was not
made here. However, the varying adjuvant activity observed with
the C4 bp a-chain oligomerization domain from different species
when fused to the PyMSP119 protein vaccine, or an unrelated
oligomerization domain [10], could be due to the variable stability
and strength of oligomers formed [36].
We hypothesized that adjuvant activity may occur due to the
oligomerization domain binding to CRP and SAP, which then
bind to FccR, resulting in enhanced innate and adaptive
immunity. Whilst our data indicate that the FcR common c-
chain is not required for adjuvant activity, it remains to be
investigated whether antigens fused to C4 bp and expressed by the
viral vectors bind to CRP and SAP at all, and therefore their
possible role in adjuvant activity cannot be excluded. Further
studies will need to be carried out to determine whether binding of
IMX313 to these soluble pentraxins occurs, in agreement with
published data for the full-length C4 bp molecule [19–21], and
whether this is important in adjuvant activity.
Particulate antigens, such as oligomerized proteins, are known
to be a better target for both cross-presentation [37,38] and
phagocytosis and this may potentially explain the ability of these
domains to enhance antigen-specific T cell responses following
both MVA and AdHu5 expression. However, greater uptake by
C4 bp Can Adjuvant Adenoviral Vectored Vaccines
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phagocytosis might be expected to enhance antibody (as well as T
cell) responses, but surprisingly, following a single or double
AdHu5 vaccination, no differences in total IgG induction were
observed for any antigen when fused to the oligomerization
domain either in BALB/c mice or rabbits. However, enhanced
antigen-specific antibody responses were observed in mice
following MVA-MVA PyMSP142, and have been reported
previously following Ad-MVA [11] or protein [10] immunization.
This suggests that administration of MVA or protein is necessary
for enhanced antibody responses following immunization with a
vaccine containing IMX108 or IMX313. Whilst protein vaccines
administered as heptameric particles may be more suited for
antibody induction, differences in cellular tropism and/or innate
immune responses to MVA versus AdHu5 may explain the ability
of the oligomerized antigen to better stimulate B cell responses in
the context of poxviral expression. These differences remain to be
further investigated. In future studies it would also be interesting to
compare boosting with IMX313 conjugated protein vaccines and
MVA vaccines. We have extensively tested the utility of
adenoviral-prime protein-boost regimes in mice and rhesus
macaques [3,30,39], and a Phase Ia clinical trial of this approach
is currently underway with the PfAMA1 antigen (ClinicalTrials.-
gov, Identifier NCT01351948). Although we have shown protein
vaccines can boost T cell responses in mice, in head-to-head
comparisons MVA is superior at boosting T cell responses in the
absence of IMX313 [30,39].
Overall, these data demonstrate that C4 bp a-chain oligomer-
ization domains can effectively enhance antigen-specific CD8+ T
cell responses induced by AdHu5 vectored vaccines expressing
certain antigens, and that this effect is unaltered in FcR c-chain
knockouts. CD4+ T cell responses were low in this study and were
only marginally increased by the addition of the oligomerization
domain to the vaccine construct. We have not investigated the
causes of antigen-dependence, but speculate that this adjuvant
activity requires not only oligomerization of the antigen, but also
its efficient secretion. Few adjuvants are known to significantly
enhance T cell responses from viral vectored vaccines – a
technology that is fast becoming a leading and clinically-relevant
subunit vaccine delivery platform [1]. Given that the maximum
achievable T cell responses are likely required to provide
protective efficacy against cancers and difficult infectious diseases,
IMX313, which has been optimized for use in humans, remains a
strong candidate for assessment in T cell-inducing vaccine antigen
constructs.
Figure 5. Adjuvanticity of IMX313 in rabbits following immunization with AdHu5-PfAMA1. New Zealand white rabbits were immunized
i.m. with 16109 or 56107 ifu AdHu5-PfAMA16IMX313, 56 days later they were given a homologous boost. Serum was taken on days 0, 14, 55, 70 and
84 and IgG titers were measured by ELISA (A). Median titer and range for n = 4 rabbits/group are shown. The arrows indicate the times of
immunization. Purified IgG from day 84 post-immunization was assayed for GIA (B). Data presented are percentage inhibition for individual rabbits
relative to the parasite growth observed without sera using purified IgG at 2.5 mg/mL. The non-linear regression curve is shown. Data show the
results of a single experiment.
doi:10.1371/journal.pone.0044943.g005
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Materials and Methods
Ethics Statement
Animal procedures were carried out according to the UK
Animals (Scientific Procedures) Act 1986 and were approved by
the University of Oxford Animal Care and Ethical Review
Committee (PPL 30/2414).
Recombinant AdHu5 and MVA Vaccines
AdHu5 and MVA vectors expressing PyMSP142 with or
without IMX108 (Ad42-IMX108 and Ad42-Nil) have been
previously described [11]. AdHu5 and MVA vectors expressing
the P. falciparum AMA1 (3D7 strain) antigen (AdAMA1-Nil) and P.
falciparum MSP1 (PfM128) antigen (AdPfM128-Nil) have also been
described elsewhere [23,24,30]. Vectors expressing these P. falci-
parum antigens fused at the C-terminus to the 55 amino acid
IMX313 motif (PfAMA1-IMX313 and PfM128-IMX313) were
made by similar methods. Adenoviruses were titered for both the
number of viral particles (vp) by UV spectrophotometry [11] and
the number of infectious units (ifu) by immunostaining. Immuno-
staining was carried out by infection of T-RExTM-293 cells
(Invitrogen) with serial dilutions of virus. Forty-eight hours post
infection cells were stained with anti-hexon antibody and detected
with HRP-conjugated secondary antibody (Cambridge Biosci-
ence).
Animals and Immunizations
All mouse experiments were carried out in specific pathogen-
free conditions. 6–8 week old female BALB/c mice were obtained
from Harlan, UK, or Charles River Laboratories, UK. Fc-
receptor common c-chain deficient mice [40,41] on a BALB/c
background (FcRc2/2) were provided from the Queen’s Medical
Centre, Nottingham, UK and bred at the Wellcome Trust Centre
for Human Genetics, Oxford, UK. Genotype was confirmed using
DNA extracted from tissue samples and the Expand High Fidelity
PCR Kit (Roche Diagnostics, UK) and previously described
reaction conditions and primers (http://jaxmice.jax.org/strain/
002847.html) except that a final concentration of 4 mM MgCl2
was used. Experiments in New Zealand white rabbits were carried
out at Spring Valley Laboratories, USA.
All vaccines were formulated in endotoxin free PBS and given
intramuscularly (i.m.) or intradermally (i.d.) in a total volume of
Figure 6. Adjuvanticity of IMX108 in FcRc2/2mice. Wildtype or FcRc2/2 mice were immunized i.m. with 1.56109 ifu Ad42-IMX108 or Ad42-Nil.
Two weeks later PyMSP133-specific IFN-c, TNFa and IL-2 positive CD8
+ T cells in the spleen were measured by ICS (A). Box and whisker plots show
median, IQR and range for n = 7–13 mice/group. PyMSP119-specific total IgG was measured by ELISA (B). Points indicate individual mice and bars
indicate median titer. n = 6 mice/group. *P,0.05, **P,0.01, by Mann Whitney test. Combined data are shown from two independent experiments.
doi:10.1371/journal.pone.0044943.g006
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50 mL (25 mL/leg or ear) to mice and 100 mL (50 mL/leg) to
rabbits. There was an eight-week interval between prime and
boost vaccinations.
Isolation of Cells
Mouse spleens were mechanically homogenized in PBS, passed
through a 70 mm cell strainer and erythrocytes were removed by
re-suspension of cells in ACK lysis buffer for 5 min. The reaction
was stopped with PBS, then cells were centrifuged and re-
suspended in complete MEM (10% Foetal Calf Serum, Pen/Strep,
L-glutamine and 2-Mercaptoethanol). For isolation of PBMC, 7–
10 drops of blood were collected from the tail vein into 200 mL
10 mM EDTA in PBS. Erythrocytes were removed by incubation
with ACK lysis buffer and cells were re-suspended in complete
MEM.
Peptides
PyMSP1 responses were measured using a pool of 55 peptides
spanning the entire length of PyMSP133 [11,42,43]. These were
each 15 amino acids (aa) long and overlapped by 10aa. PfAMA1
responses were measured following stimulation with a pool of three
PfAMA1 peptides, which include one H2d CD8+ T cell
(KYVKNLDELTLCSRH) and two H-2d CD4+ T cell epitopes
(VFGKGIIIENSKTTF and NKKIIAPRIFISDDK). Antigen-spe-
cific responses against P. falciparum MSP133 (Wellcome strain)
following PfM128 immunization were measured using the two
overlapping peptides encoding a known H-2d CD8+ T cell epitope
(NKEKRDKFLSSYNYI and DKFLSSYNYIKDSID) [23].
Multi-parameter Flow Cytometry
Splenocytes or PBMC were incubated for 5 h at 37uC in the
presence of 1:1000 GolgiPlug (Brefeldin A) and 1 mg/mL of each
peptide or peptide pool. Samples were then stored at 4uC
overnight. Cells were centrifuged, re-suspended in 1:100 Fc-block
(anti-CD32/CD16) and incubated for 15 min, washed once in
PBS and then incubated for 30 min with 1:100 anti-CD4
PacificBlue or APC-Alexa750 (Clone GK1.5) and anti-CD8
PerCP-Cy5.5 or PacificBlue (Clone 53–6.7) in PBS. Cells were
then washed twice in PBS and then permeabilized by incubation
with Cytofix/Cytoperm for 15 min. The reaction was stopped by
addition of PermWash, cells were washed in PermWash and then
incubated for 30 min with anti-IFN-c APC or PE (clone
XMG1.2), anti-TNFa FITC or APC (clone MP6-XP22) and
anti-IL-2 PE or FITC (clone JES6–54), all diluted 1:100 in
PermWash. Finally cells were washed twice in PermWash then re-
suspended in PBS and samples were run on a CyAN ADP flow
cytometer (Dako, UK). Data were analyzed using Flowjo v8.8.7.
The gating strategy used is shown in Figure S2. For multi-
functional analysis, boolean gates were used and data presented
using Pestle v1.6.2 and SPICE v 5.1 [44]. Background responses in
un-stimulated cells were subtracted from stimulated responses
prior to analysis.
Ex vivo IFN-c ELISPOT
ELISPOT assays specific for IFN-c were carried out as
previously described [45] using coating and detecting antibodies
from Mabtech. Briefly, plates were coated with anti-IFN-c
antibodies overnight, plates were then washed and blocked before
addition of splenocytes and the indicated peptides at 1 mg/mL and
incubation for 18–20 h at 37uC. Plates were then washed and
responses detected by addition of a biotin-conjugated rat anti-
mouse IFN-c antibody, before addition of Streptavidin Alkaline
Phosphatase polymer and development with Biorad AP conjugate
development buffer. Cells were plated in duplicate and the mean
response in spot forming units (SFU) per 106 PBMC was
calculated. Responses from un-stimulated control wells were
subtracted.
ELISA
Mouse total IgG was measured by ELISA as previously
described [11]. 96-well Nunc-immuno Maxisorp plates were
coated with PyMSP119-GST fusion protein [11], recombinant
3D7 PfAMA1 protein (a gift from Dr Chetan Chitnis (ICGEB,
New Delhi, India)) [3,24] or 3D7 PfMSP119-GST fusion protein
[23] at a concentration of 2 mg/mL in PBS. All serum samples
were diluted 1:100 in PBS containing 0.05% Tween and then
diluted three-fold down the plate. Optical density was read at
405 nm (OD405) and endpoint titer calculated as the x-axis
intercept of the dilution curve at an absorbance value 3 SD greater
than the OD405 for naı¨ve mouse serum. Samples were tested in
duplicate and a reference control serum was included in all assays.
Rabbit IgG ELISAs were carried out using a standardized
protocol at the GIA reference center (LMVR, NIAID, NIH)
using 3D7 PfAMA1 antigen provided by David Narum at the
Laboratory of Malaria Immunology and Vaccinology, NIH, USA.
A standard curve was generated using reference sera run in
duplicate on every plate and one ELISA unit is the reciprocal
dilution required to give an O.D. of 1 in the standardized assay
[32].
GIA
Polyclonal rabbit IgG was purified from serum samples by
Protein G affinity chromatography and adjusted to a concentra-
tion of 10 mg/mL in incomplete RPMI. A standardized assay of in
vitro growth inhibitory activity (GIA) was carried out at the GIA
reference center (LMVR, NIAID, NIH) as previously described
[32]. Rabbit IgG from individual animals were tested at a final
concentration of 5 mg/mL and 2.5 mg/mL against 3D7 clone
P. falciparum parasites.
Western Blotting
Cell lysate was prepared by infection of 293 cells with the
indicated AdHu5 vaccines at an MOI of 5 infectious units. Thirty
hours post infection, the media was removed, cells were washed
once with PBS, scraped, centrifuged and re-suspended in non-
reducing or reducing Laemmli’s sample buffer. Cells were then
heated at 95uC for 5 min and sonicated for 1 min before storage at
220uC until use. For Western blotting, samples were separated by
SDS-PAGE on an 8–16% polyacrylamide pre-cast gel (Pierce) in
Tris-HEPES-SDS running buffer (100 mM Tris, 100 mM
HEPES, 1% SDS, pH 8.0). Proteins were blotted onto a
nitrocellulose membrane (Biorad) by electrophoretic transfer.
The membrane was then washed twice in PBS, blocked for 1 h
with 3% BSA/PBS, washed again, incubated for 1 h in antigen-
specific primary antibody (Ab) diluted 1:1000 in 3% BSA/PBS,
washed, incubated for 1 h with donkey anti-mouse-alkaline
phosphatase diluted 1:3000, washed, and finally developed with
BCIP/NBT solution (Sigma). Colorplus prestained protein ladder,
broad range (10–230 kDa) (NEB), was included to determine the
size of the proteins. Control proteins and non-recombinant
AdHu5 infected lysate were included on each gel to confirm that
primary Ab was antigen specific. Antibody for detecting PfM128
antigen was polyclonal sera from mice immunized three times with
recombinant PfMSP119 protein [39] and for detecting PfAMA1
antigen polyclonal sera was used from mice immunized with viral
vectored vaccines (ChAd63-MVA) encoding PfAMA1 [24].
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Statistics
Data were analyzed using GraphPad Prism v5.01. The
normality of the data was determined using the Kolmogorov-
Smirnov one-sample test. For non-parametric data, two groups
were compared using a Mann-Whitney test and data are presented
as median with individual data points, or box and whisker plots
representing median, interquartile range (IQR) and range. ELISA
titers were logarithmically (log 10) transformed in order to
normalize the data and allow parametric analysis. In all cases
P,0.05 was considered significant (*P,0.05, **P,0.01 and
***P,0.001).
Supporting Information
Figure S1 Adjuvant activity of IMX108 following AdHu5
vaccine dosing based on viral particles (vp). BALB/c mice
were immunized with 161010 vp or 16108 vp Ad42-IMX108 or
Ad42-Nil by either the i.m. or i.d. route as indicated. Two weeks
later frequency of PyMSP133-specific IFN-c, TNFa and IL-2
positive CD8+ splenic T cells was measured by ICS. Box and
whisker plots show median, IQR and range for n = 5 mice/group.
**P,0.01, *P,0.05 by Mann Whitney test compared to the
Ad42-IMX108 given by the same dose and route.
(TIFF)
Figure S2 Representative ICS gating strategy. All cellular
marker and cytokine gates were drawn with forward scatter (FS
(lin)) on the x axis. Cell clumps, doublets and triplets were
excluded by gating on single cells in a plot showing FS (area)
against FS (lin). Lymphocytes were then selected on FS against side
scatter (SS (lin)). CD8+ cells were selected by first selecting CD42
cells to ensure that CD4+CD8+ cells were excluded. Within the
CD42 cells, CD8+ cells were selected. Cytokine gates were then
drawn for the CD8+ cells as shown and background from
unstimulated cells subtracted. A similar gating strategy (including
a CD82 gate) was used for selecting CD4+ cells.
(EPS)
Figure S3 Adjuvant activity of IMX313 following Ad-
AMA1 immunisation assessed by IFN-c ELISPOT. BALB/
c mice were immunized i.m. with 16107 ifu AdHu5-PfAMA1 with
or without IMX313 (AdAMA1-IMX313 and AdAMA1-Nil).
Fourteen days later mice were culled and AMA1-specific IFN-c
positive splenocytes were measured by ELISPOT. Data shown are
spot forming units (SFU) per 106 splenocytes (n = 5 mice per
group). Box and whisker plots indicate median, IQR and range.
(TIFF)
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